Dr. Cora Sternberg first talks about urothelial cancer, and the Keynote-45 study on immunotherapy: some data on qualityof life, they are really important.
Is There Sufficient Evidence to Intensify Systemic Therapy in Patients With Prostate Cancer Who Have M1 by PSMA-PET but Negative Conventional Imaging?
ESMO 2024: Cora Sternberg video interview about her presentation on event-free survival (EFS) as a surrogate endpoint for overall survival in muscle-invasive bladder cancer.
This project received funding from the European Research Council (ERC) and from the Samuel and Barbara Sternberg Foundation.
The INSIDE-PC study provides evidence of the potential of AI systems in medical literature searches on complex clinical questions.
ESMO Congress 2024 - European Society for Medical Oncology Barcellona 13-17 Settembre 2024
In this video Cora Sternberg talks about efficacy and safety of darolutamide in combination with androgen deprivation therapy and docetaxel by disease, volume and risk in the phase three Arasens study.
In this video Dr. Cora Sternberg discusses new developments in the treatment of urothelial carcinoma.
In this interview for UroToday dr. Cora Sternberg presents the latest data and ongoing clinical trials in the context of prostate cancer.
Alicia Morgans speaks with Cora Sternberg about the EV-302 study presented at ESMO 2023. This study marks a significant shift in treating advanced metastatic urothelial cancer, traditionally managed with cisplatin or carboplatin-based chemotherapy.
Exploration of therapeutic vulnerabilities exposed by 9p21 loss in bladder cancer cell lines.
Dr. Cora Sternberg lecture: Precision medicine for prostate cancer
Precision medicine is an emerging approach to the treatment and prevention of diseases that takes into account the individual variability of each person's genes, environment and lifestyle.
